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man, who was transplanted for hepatocellular carcinoma arising
from cirrhosis associated with non-alcoholic fatty liver and dia-
betes. Because of co-existent well-compensated idiopathic famil-
ial pulmonary ﬁbrosis and family history of cryptogenic cirrhosis,
he was screened and found positive for a novel c.2062 C>G telo-
merase (TERT) mutation, encoding for the protein Glu668Asp var-
iant, which was also conﬁrmed in the neoplastic tissue. TERT
mutations have very recently been associated with a spectrum
of familial hepatic liver diseases often characterized by steatosis
and hepatic iron overload, and have been reported to represent a
frequent risk factor for cirrhosis, being observed in as much as
3–8% of unselected patients with different liver diseases. Due to
the systemic involvement of telomerase diseases very likely
inﬂuencing the clinical outcome, and the peculiar biological
features of hepatocellular carcinoma arising in this context, we
suggest that patients with cryptogenic cirrhosis or other sugges-
tive features should be screened for TERT mutations and speciﬁc
treatment algorithms elaborated for this disease.
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We report the case of a 63-year-old man who came to our
observation for a single HCC lesion of 23 mm (Barcelona clinic
liver cancer – BCLC stage I) in the right hepatic lobe, incidentally
discovered during an ultrasonographic examination of the abdo-
men performed for mild thrombocytopenia, which was otherwise
unremarkable except for steatosis. The family history was nota-
ble for cirrhosis associated with iron overload (mother), and
restrictive lung disease (sister); the family pedigree is presented
in Fig. 1. The patient used to drink no more than 20 g of alcohol/
day during lifetime, was modestly overweight (body mass index
27.5 kg/m2), and smoked until the age of 60, when pulmonary
ﬁbrosis was diagnosed by computer tomographic scan and lung
biopsy, following the death of the sister for respiratory failure.
Afterwards, he was treated with low-dose corticosteroids, and
at 61 years of age, he developed diabetes, for which he took met-
formin, insulin, and simvastatin for dyslipidemia. Due to the opti-
mal liver function and absence of portal hypertension, after HCC
diagnosis, the patient underwent anatomical resection of the
tumoral lesion. At the time of surgery, complete blood count, iron
and copper indices, and liver enzymes were within normal limits,
except for increased gamma-glutamyltransferases (223 IU/ml;
with normal bilirubin and alkaline phosphatase), and mild mac-
rocytosis (MCV 103). He was negative for mutations in the HFE
gene of hereditary hemochromatosis, viral markers including
HBcAb, autoantibodies, and was heterozygous for the PNPLA3
p.148Met variant associated with progressive steatohepatitis
[2]. Histopathological evaluation showed non-capsulated, poorly
differentiated hepatocellular carcinoma (Edmonson grade III–IV;
Fig. 2A and B), with focal clear cell areas and with an inﬁltrating
growth pattern involving surgical margins and focal vascular
invasion. The extra-lesion liver was characterized by micronodu-
lar cirrhosis (Fig. 2C) with mild steatosis and necroinﬂammatory
features (Fig. 2D and E). As expected, based on the histological
analysis, multifocal clinical recurrence (3 lesions, the major less
than 3 cm) was detected at 4 months after close radiological
monitoring, and was treated with transarterial chemoemboliza-
tion as a bridge therapy, while the patient was immediately listed
for liver transplantation (LT) for presumed HCC in NAFLD. At pre-
surgical evaluation, chest X-ray conﬁrmed diffuse lung interstitial13 vol. 58 j 399–401
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Fig. 1. Pedigree of the proband’s family. Arrow, proband; IPF, idiopathic
pulmonary ﬁbrosis; HCC, hepatocellular carcinoma.
Case Reportinvolvement consistent with ﬁbrosis, spirometry a restrictive
syndrome (forced vital capacity (FVC) 63% of predicted, forced
expiratory volume at 1 s/forced vital capacity 125% of predicted),
blood gas analysis in ambient air pO2 62 mmHg, pCO2 40 mmHg,
HCO3 30 mEq/L, pH 7.49, spO2 93%. Combined liver–lung trans-
plantation was not chosen because of the urgency of the proce-
dure determined by the indication (HCC), and the relative
preservation of lung function before LT, which in this case was
not deemed to overcome the risks of lung transplantation. The
patient was transplanted 6 months after recurrence without
complications and began immunosuppression with tacrolimus
and everolimus. There were no hepatic complications, but despite
tacrolimus has been reported to improve the progression of the
disease in patients with idiopathic pulmonary ﬁbrosis [3], after
LT, pulmonary function rapidly worsened leading to respiratory
failure (FVC 48%), which was treated with oxygen therapy. After
multiple hospital admissions associated with upper respiratoryD E
A B
Fig. 2. Liver histology and genetic evaluation of hepatocellular carcinoma in a patien
carcinoma, showing a scarcely differentiated (A, hematoxylin and eosin (H&E) 200)
parenchyma, stained with reticulin for ﬁbrosis (C, 40) and H&E (D and E, 200). (F)
encoding the p.Glu668Asp TERT variant.
400 Journal of Hepatology 201infections, the patient died of Gram positive sepsis 4 months after
LT.
As loss-of-function mutations in the telomerase (TERT) gene
are responsible, in combination with environmental factors, for
a signiﬁcant proportion of cases of familial idiopathic pulmonary
ﬁbrosis [4,5], the patient was tested at the Department of Internal
Medicine, University of Milan, and the c.2062 C>G encoding the
p.Glu668Asp substitution in exon 5 was detected in heterozygos-
ity in the peripheral blood, 3/3 HCC samples from the explanted
liver, and extratumoral hepatic tissue (Fig. 1F). The c.2602 C>G
mutation was not previously reported in healthy subjects [6,7],
it was absent in 50 Italian healthy blood donors, and it is located
in the motif 3c of the reverse transcriptase domain of the protein,
therefore likely leading to reduced telomere length, by directly
interfering with TERT enzymatic activity [8,9]. Indeed, the
p.Glu668Asp mutation was estimated as ‘‘probably damaging’’
for TERT function by the PolyPhen v2.0 software [10] (HumVar
model, probability of functional change 0.996, sensitivity 0.36,
speciﬁcity 0.97). The patient was negative for mutations in TERC,
the gene encoding for the RNA primer of TERT, also associated
with pulmonary ﬁbrosis. The sons of the patient did not consent
to genetic testing.
Telomere diseases, exempliﬁed by dyskeratosis congenita, are
characterized by premature senescence of the stem cell compart-
ment, tissue ﬁbrosis, and increased cancer risk due to chromo-
somal instability [11]. Clinical features include hematological
alterations ranging from macrocytosis to bone marrow failure,
mucocutaneous alterations, pulmonary ﬁbrosis, diabetes, and cir-
rhosis. Besides idiopathic pulmonary ﬁbrosis, TERT mutations
have been associated with a spectrum of familial hepatic liver
diseases often characterized by steatosis and hepatic iron over-
load, possibly related to dyserythropoiesis [12], and have recently
been demonstrated to represent a frequent risk factor for cirrho-
sis, being observed in 3–8% of unselected patients with differentF
C
t with non-alcoholic fatty liver. Histopathological examination of hepatocellular
and a clear cell (B, H&E 200) area of the neoplasia, and the non-neoplastic
Electropherogram showing heterozygosity for the c.2602 C>G mutation (arrow),
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liver diseases [6,7]. Despite TERT overexpression is frequently
observed in HCC related to chronic hepatitis [13], because it
favors the replicative potential of the stem cell compartment,
HCC cases were previously reported in a few patients with TERT
mutations [7,11]. For the ﬁrst time, we demonstrate that HCC
occurs without losing the dysfunctional mutated allele in neo-
plastic tissue, suggesting that an alternative carcinogenic path-
way, likely involving chromosomal instability, ensued, that was
associated with aggressive biological features in the present case.
Furthermore, rapid progression of liver cirrhosis, aggressive
recurrence of HCC, and poor outcome after LT have been reported
in patients with TERTmutations [7], suggesting that further stud-
ies are needed to deﬁne the optimal management of liver failure
and HCC occurring in patients with TERT mutations (e.g., possible
contraindication for transplantation). Indeed, TERT mutations are
reportedly frequent, but presently are not being searched for in
clinical practice [6,7]. Lastly, this case underscores the need to
investigate in depth HCC cases arising in patients with NAFLD
or cryptogenic cirrhosis, especially if not associated with a typical
long history of obesity, which are presently classiﬁed as bona ﬁde
metabolic cirrhosis based on the co-existence of mild steatosis or
even in its absence for the so called ‘‘burn-out steatohepatitis’’
and diabetes, that however, could also result from several genetic
defects including TERT mutations.Financial support
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